NCT05180422View on ClinicalTrials.gov

A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable or Metastatic KRAS G12C Mutant NSCLC With Asymptomatic Brain Metastasis

PHASE1/PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

June 15, 2022

Primary Completion Date

January 31, 2023

Study Completion Date

January 31, 2023

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

AMG 510

Continuous once daily (QD) oral dosing (Days 1-21 each cycle) with or without food.

DRUG

MVASI

Intravenous (i.v.) infusion every 21 days (i.e. Day 1 of each 21-day cycle).

Trial Locations (1)

37232

Vanderbilt Ingram Cancer Center, Nashville

Sponsors

Lead Sponsor

Criterium, Inc.

Collaborators (1)

Amgen
All Listed Sponsors
collaborator

Amgen

INDUSTRY

lead

Criterium, Inc.

INDUSTRY

NCT05180422 - A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable or Metastatic KRAS G12C Mutant NSCLC With Asymptomatic Brain Metastasis | Biotech Hunter | Biotech Hunter